Universal Beteiligungs und Servicegesellschaft mbH Buys 12,197 Shares of Insulet Corporation $PODD

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Insulet by 9.8%, buying 12,197 shares to hold 137,158 shares (~0.19%) valued at about $39.08 million.
• Insulet beat Q1 expectations with EPS of $1.55 (vs. $1.48) and revenue of $783.8M (up 31.2% year‑over‑year); analysts give a "Moderate Buy" consensus with an average price target of $327.24.
• Director Michael R. Minogue purchased 2,030 shares at $246.23 (~$499,847), raising his holdings to 17,483 shares and contributing to insider ownership of 0.39%.

Universal Beteiligungs und Servicegesellschaft mbH grew its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 9.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 137,158 shares of the medical instruments supplier's stock after buying an additional 12,197 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.19% of Insulet worth $39,080,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PODD. Worldquant Millennium Advisors LLC bought a new position in Insulet during the second quarter worth about $80,082,000. Squarepoint Ops LLC lifted its holdings in shares of Insulet by 11,905.8% during the 3rd quarter. Squarepoint Ops LLC now owns 227,270 shares of the medical instruments supplier's stock valued at $70,165,000 after purchasing an additional 225,377 shares in the last quarter. Qube Research & Technologies Ltd lifted its holdings in shares of Insulet by 37.3% during the 3rd quarter. Qube Research & Technologies Ltd now owns 574,365 shares of the medical instruments supplier's stock valued at $177,324,000 after purchasing an additional 156,009 shares in the last quarter. Parnassus Investments LLC bought a new position in shares of Insulet during the 3rd quarter valued at about $46,525,000. Finally, Nordea Investment Management AB lifted its holdings in shares of Insulet by 35.0% during the 4th quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier's stock valued at $157,128,000 after purchasing an additional 142,922 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Weiss Ratings reiterated a "hold (c)" rating on shares of Insulet in a report on Thursday, January 22nd. Rothschild & Co Redburn set a $220.00 price objective on Insulet in a report on Friday. Canaccord Genuity Group cut their price objective on Insulet from $450.00 to $435.00 and set a "buy" rating on the stock in a report on Wednesday, February 18th. Barclays reiterated an "underweight" rating and set a $286.00 price objective on shares of Insulet in a report on Thursday, February 19th. Finally, Sanford C. Bernstein cut their price objective on Insulet from $380.00 to $330.00 and set an "outperform" rating on the stock in a report on Thursday, February 19th. Nineteen investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $327.24.

Insider Buying and Selling at Insulet

In related news, Director Michael R. Minogue purchased 2,030 shares of the stock in a transaction on Wednesday, February 25th. The shares were purchased at an average price of $246.23 per share, with a total value of $499,846.90. Following the transaction, the director directly owned 17,483 shares of the company's stock, valued at $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.39% of the stock is owned by company insiders.

Insulet Trading Down 0.7%

NASDAQ PODD opened at $192.21 on Friday. The stock has a market capitalization of $13.31 billion, a price-to-earnings ratio of 54.92, a PEG ratio of 1.16 and a beta of 1.47. The stock's 50 day moving average price is $223.29 and its two-hundred day moving average price is $272.57. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81. Insulet Corporation has a 52 week low of $189.63 and a 52 week high of $354.88.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, beating the consensus estimate of $1.48 by $0.07. The firm had revenue of $783.80 million for the quarter, compared to analysts' expectations of $768.31 million. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The business's quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.15 EPS. As a group, analysts anticipate that Insulet Corporation will post 6.16 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.